AstraZeneca PLC (AZN)vsVanda Pharmaceuticals Inc (VNDA)
AZN
AstraZeneca PLC
$185.48
-0.59%
HEALTHCARE · Cap: $293.73B
VNDA
Vanda Pharmaceuticals Inc
$3.95
-4.82%
HEALTHCARE · Cap: $230.99M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 27109% more annual revenue ($62.38B vs $229.28M). AZN leads profitability with a 17.7% profit margin vs -119.9%. AZN appears more attractively valued with a PEG of 1.35. AZN earns a higher WallStSmart Score of 68/100 (B-).
AZN
Strong Buy68
out of 100
Grade: B-
VNDA
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.3%
Fair Value
$197.94
Current Price
$185.48
$12.46 discount
Margin of Safety
+83.7%
Fair Value
$37.45
Current Price
$3.95
$33.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 29.6%
Earnings expanding 23.5% YoY
Generating 4.0B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.1% year-over-year
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Expensive relative to growth rate
Smaller company, higher risk/reward
Weak financial health signals
ROE of -60.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 29.6%. PEG of 1.35 suggests the stock is reasonably priced for its growth.
Bull Case : VNDA
The strongest argument for VNDA centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.1% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : VNDA
The primary concerns for VNDA are PEG Ratio, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
AZN profiles as a mature stock while VNDA is a growth play — different risk/reward profiles.
VNDA carries more volatility with a beta of 0.73 — expect wider price swings.
VNDA is growing revenue faster at 24.1% — sustainability is the question.
AZN generates stronger free cash flow (4.0B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (68/100 vs 42/100), backed by strong 17.7% margins. VNDA offers better value entry with a 83.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Vanda Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company is headquartered in Washington, the District of Columbia.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?